Estrogen-mediated neuroprotection after experimental stroke in male rats

Thomas J Toung, Richard J. Traystman, Patricia D. Hurn

Research output: Contribution to journalArticle

Abstract

Background and Purpose - We have previously shown that 17β-estradiol reduces infarction volume in female rats. The present study determined whether single injection or chronic implantation of estrogen confers neuroprotection in male animals with middle cerebral artery occlusion (MCAO) and whether there is an interaction with endogenous testosterone. Methods - Male Wistar rats were treated with 2 hours of reversible MCAO. In protocol 1, acute versus chronic estrogen administration was examined in groups receiving the following: Premarin (USP) 1 mg/kg IV, immediately before MCAO (Acute, n=13, plasma estradiol = 171±51 pg/mL); 7 days of 25 μg (E25, n=10, 10±3 pg/mL) or 100 μg 17β-estradiol (E100, n=12, 69±20 pg/mL) by subcutaneous implant; or saline (SAL, n=21, 3±1 pg/mL). Laser-Doppler flowmetry was used to monitor the ipsilateral parietal cortex throughout the ischemic period and early reperfusion. At 22 hours of reperfusion, infarction volume was determined by 0 2,3,5-triphenyltetrazolium chloride staining and image analysis. In protocol 2, rats were castrated to deplete endogenous testosterone and then treated with estradiol implants: castration only (CAST, n=13, estradiol = 5±2 pg/mL), sham-operated (SHAM, n=10, 4±2 pg/mL), estradiol implant 25 μg (CAST+E25, n=16, 7±2 pg/mL) or 100 μg (CAST+E100, n=14, 77±14 pg/mL). Results - Cortical infarct volumes were reduced in all estrogen-treated groups: Acute (21±4% of ipsilateral cortex), E25 (12±5%), and E100 (12±3%) relative to SAL (38±5%). Caudate infarction was similarly decreased: Acute (39±7% of ipsilateral striatum), E25 (25±7%), and E100 (34±6%) relative to SAL (63±4%). Castration did not alter ischemic outcome; cortical and caudate infarction (percentage of respective ipsilateral regions) were 37±5% and 59±5% in CAST and 39±7% and 57±5% in SHAM, respectively. Estrogen replacement reduced infarction volume in castrated animals in cortex (19±4% in CAST+E25 and 12±4% in CAST+E100) and in caudate (42±6% in CAST+25 and 20±7% in CAST+100). Laser-Doppler flowmetry results during ischemia and reperfusion was not different among groups. Conclusions - Both acute and chronic 17β-estradiol treatments protect male brain in experimental stroke. Testosterone availability does not alter estradiol- mediated tissue salvage after MCAO.

Original languageEnglish (US)
Pages (from-to)1666-1670
Number of pages5
JournalStroke
Volume29
Issue number8
StatePublished - Aug 1998

Fingerprint

Estradiol
Estrogens
Stroke
Infarction
Middle Cerebral Artery Infarction
Reperfusion
Testosterone
Laser-Doppler Flowmetry
Castration
Conjugated (USP) Estrogens
Parietal Lobe
Estrogen Replacement Therapy
Neuroprotection
Wistar Rats
Ischemia
Staining and Labeling
Injections
Brain

Keywords

  • Cerebral ischemia
  • Estrogen
  • Neuroprotection
  • Rats
  • Stroke
  • Testosterone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Toung, T. J., Traystman, R. J., & Hurn, P. D. (1998). Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke, 29(8), 1666-1670.

Estrogen-mediated neuroprotection after experimental stroke in male rats. / Toung, Thomas J; Traystman, Richard J.; Hurn, Patricia D.

In: Stroke, Vol. 29, No. 8, 08.1998, p. 1666-1670.

Research output: Contribution to journalArticle

Toung, TJ, Traystman, RJ & Hurn, PD 1998, 'Estrogen-mediated neuroprotection after experimental stroke in male rats', Stroke, vol. 29, no. 8, pp. 1666-1670.
Toung, Thomas J ; Traystman, Richard J. ; Hurn, Patricia D. / Estrogen-mediated neuroprotection after experimental stroke in male rats. In: Stroke. 1998 ; Vol. 29, No. 8. pp. 1666-1670.
@article{6b2e1f0cfc1c41adaf23d597667a9306,
title = "Estrogen-mediated neuroprotection after experimental stroke in male rats",
abstract = "Background and Purpose - We have previously shown that 17β-estradiol reduces infarction volume in female rats. The present study determined whether single injection or chronic implantation of estrogen confers neuroprotection in male animals with middle cerebral artery occlusion (MCAO) and whether there is an interaction with endogenous testosterone. Methods - Male Wistar rats were treated with 2 hours of reversible MCAO. In protocol 1, acute versus chronic estrogen administration was examined in groups receiving the following: Premarin (USP) 1 mg/kg IV, immediately before MCAO (Acute, n=13, plasma estradiol = 171±51 pg/mL); 7 days of 25 μg (E25, n=10, 10±3 pg/mL) or 100 μg 17β-estradiol (E100, n=12, 69±20 pg/mL) by subcutaneous implant; or saline (SAL, n=21, 3±1 pg/mL). Laser-Doppler flowmetry was used to monitor the ipsilateral parietal cortex throughout the ischemic period and early reperfusion. At 22 hours of reperfusion, infarction volume was determined by 0 2,3,5-triphenyltetrazolium chloride staining and image analysis. In protocol 2, rats were castrated to deplete endogenous testosterone and then treated with estradiol implants: castration only (CAST, n=13, estradiol = 5±2 pg/mL), sham-operated (SHAM, n=10, 4±2 pg/mL), estradiol implant 25 μg (CAST+E25, n=16, 7±2 pg/mL) or 100 μg (CAST+E100, n=14, 77±14 pg/mL). Results - Cortical infarct volumes were reduced in all estrogen-treated groups: Acute (21±4{\%} of ipsilateral cortex), E25 (12±5{\%}), and E100 (12±3{\%}) relative to SAL (38±5{\%}). Caudate infarction was similarly decreased: Acute (39±7{\%} of ipsilateral striatum), E25 (25±7{\%}), and E100 (34±6{\%}) relative to SAL (63±4{\%}). Castration did not alter ischemic outcome; cortical and caudate infarction (percentage of respective ipsilateral regions) were 37±5{\%} and 59±5{\%} in CAST and 39±7{\%} and 57±5{\%} in SHAM, respectively. Estrogen replacement reduced infarction volume in castrated animals in cortex (19±4{\%} in CAST+E25 and 12±4{\%} in CAST+E100) and in caudate (42±6{\%} in CAST+25 and 20±7{\%} in CAST+100). Laser-Doppler flowmetry results during ischemia and reperfusion was not different among groups. Conclusions - Both acute and chronic 17β-estradiol treatments protect male brain in experimental stroke. Testosterone availability does not alter estradiol- mediated tissue salvage after MCAO.",
keywords = "Cerebral ischemia, Estrogen, Neuroprotection, Rats, Stroke, Testosterone",
author = "Toung, {Thomas J} and Traystman, {Richard J.} and Hurn, {Patricia D.}",
year = "1998",
month = "8",
language = "English (US)",
volume = "29",
pages = "1666--1670",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Estrogen-mediated neuroprotection after experimental stroke in male rats

AU - Toung, Thomas J

AU - Traystman, Richard J.

AU - Hurn, Patricia D.

PY - 1998/8

Y1 - 1998/8

N2 - Background and Purpose - We have previously shown that 17β-estradiol reduces infarction volume in female rats. The present study determined whether single injection or chronic implantation of estrogen confers neuroprotection in male animals with middle cerebral artery occlusion (MCAO) and whether there is an interaction with endogenous testosterone. Methods - Male Wistar rats were treated with 2 hours of reversible MCAO. In protocol 1, acute versus chronic estrogen administration was examined in groups receiving the following: Premarin (USP) 1 mg/kg IV, immediately before MCAO (Acute, n=13, plasma estradiol = 171±51 pg/mL); 7 days of 25 μg (E25, n=10, 10±3 pg/mL) or 100 μg 17β-estradiol (E100, n=12, 69±20 pg/mL) by subcutaneous implant; or saline (SAL, n=21, 3±1 pg/mL). Laser-Doppler flowmetry was used to monitor the ipsilateral parietal cortex throughout the ischemic period and early reperfusion. At 22 hours of reperfusion, infarction volume was determined by 0 2,3,5-triphenyltetrazolium chloride staining and image analysis. In protocol 2, rats were castrated to deplete endogenous testosterone and then treated with estradiol implants: castration only (CAST, n=13, estradiol = 5±2 pg/mL), sham-operated (SHAM, n=10, 4±2 pg/mL), estradiol implant 25 μg (CAST+E25, n=16, 7±2 pg/mL) or 100 μg (CAST+E100, n=14, 77±14 pg/mL). Results - Cortical infarct volumes were reduced in all estrogen-treated groups: Acute (21±4% of ipsilateral cortex), E25 (12±5%), and E100 (12±3%) relative to SAL (38±5%). Caudate infarction was similarly decreased: Acute (39±7% of ipsilateral striatum), E25 (25±7%), and E100 (34±6%) relative to SAL (63±4%). Castration did not alter ischemic outcome; cortical and caudate infarction (percentage of respective ipsilateral regions) were 37±5% and 59±5% in CAST and 39±7% and 57±5% in SHAM, respectively. Estrogen replacement reduced infarction volume in castrated animals in cortex (19±4% in CAST+E25 and 12±4% in CAST+E100) and in caudate (42±6% in CAST+25 and 20±7% in CAST+100). Laser-Doppler flowmetry results during ischemia and reperfusion was not different among groups. Conclusions - Both acute and chronic 17β-estradiol treatments protect male brain in experimental stroke. Testosterone availability does not alter estradiol- mediated tissue salvage after MCAO.

AB - Background and Purpose - We have previously shown that 17β-estradiol reduces infarction volume in female rats. The present study determined whether single injection or chronic implantation of estrogen confers neuroprotection in male animals with middle cerebral artery occlusion (MCAO) and whether there is an interaction with endogenous testosterone. Methods - Male Wistar rats were treated with 2 hours of reversible MCAO. In protocol 1, acute versus chronic estrogen administration was examined in groups receiving the following: Premarin (USP) 1 mg/kg IV, immediately before MCAO (Acute, n=13, plasma estradiol = 171±51 pg/mL); 7 days of 25 μg (E25, n=10, 10±3 pg/mL) or 100 μg 17β-estradiol (E100, n=12, 69±20 pg/mL) by subcutaneous implant; or saline (SAL, n=21, 3±1 pg/mL). Laser-Doppler flowmetry was used to monitor the ipsilateral parietal cortex throughout the ischemic period and early reperfusion. At 22 hours of reperfusion, infarction volume was determined by 0 2,3,5-triphenyltetrazolium chloride staining and image analysis. In protocol 2, rats were castrated to deplete endogenous testosterone and then treated with estradiol implants: castration only (CAST, n=13, estradiol = 5±2 pg/mL), sham-operated (SHAM, n=10, 4±2 pg/mL), estradiol implant 25 μg (CAST+E25, n=16, 7±2 pg/mL) or 100 μg (CAST+E100, n=14, 77±14 pg/mL). Results - Cortical infarct volumes were reduced in all estrogen-treated groups: Acute (21±4% of ipsilateral cortex), E25 (12±5%), and E100 (12±3%) relative to SAL (38±5%). Caudate infarction was similarly decreased: Acute (39±7% of ipsilateral striatum), E25 (25±7%), and E100 (34±6%) relative to SAL (63±4%). Castration did not alter ischemic outcome; cortical and caudate infarction (percentage of respective ipsilateral regions) were 37±5% and 59±5% in CAST and 39±7% and 57±5% in SHAM, respectively. Estrogen replacement reduced infarction volume in castrated animals in cortex (19±4% in CAST+E25 and 12±4% in CAST+E100) and in caudate (42±6% in CAST+25 and 20±7% in CAST+100). Laser-Doppler flowmetry results during ischemia and reperfusion was not different among groups. Conclusions - Both acute and chronic 17β-estradiol treatments protect male brain in experimental stroke. Testosterone availability does not alter estradiol- mediated tissue salvage after MCAO.

KW - Cerebral ischemia

KW - Estrogen

KW - Neuroprotection

KW - Rats

KW - Stroke

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=0031904678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031904678&partnerID=8YFLogxK

M3 - Article

C2 - 9707210

AN - SCOPUS:0031904678

VL - 29

SP - 1666

EP - 1670

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -